Sunovion touts pivotal Ph3 trial for Parkinson ’s drug

Gearing up for a springtime FDA submission, Sunovion Pharmaceuticals reported today that its apomorphine sublingual film succeeded in a pivotal Phase III trial in patients with Parkinson’s disease who experience motor fluctuations.
Without revealing the study’s full results, the Marlborough, Mass.-based company said that the trial met its primary and key secondary endpoints and that the drug was generally well-tolerated by patients.
Get the full story at our sister site, Drug Delivery Business News.
The post Sunovion touts pivotal Ph3 trial for Parkinson’s drug appeared first on MassDevice.

Source: Mass Device - January 30, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Neurological Pharmaceuticals Wall Street Beat Acorda Therapeutics Sunovion Pharmaceuticals Source Type: news